These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 9811854)
1. v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. Laezza C; Di Marzo V; Bifulco M Proc Natl Acad Sci U S A; 1998 Nov; 95(23):13646-51. PubMed ID: 9811854 [TBL] [Abstract][Full Text] [Related]
2. Farnesylamine: an inhibitor of farnesylation and growth of ras-transformed cells. Kothapalli R; Guthrie N; Chambers AF; Carroll KK Lipids; 1993 Nov; 28(11):969-73. PubMed ID: 8277827 [TBL] [Abstract][Full Text] [Related]
3. Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state. Laezza C; Fiorentino L; Pisanti S; Gazzerro P; Caraglia M; Portella G; Vitale M; Bifulco M J Mol Med (Berl); 2008 Dec; 86(12):1341-51. PubMed ID: 18779944 [TBL] [Abstract][Full Text] [Related]
4. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in FRTL-5 cells. II. Down-regulation by v-K-ras oncogene. Perillo B; Tedesco I; Laezza C; Santillo M; Romano A; Aloj SM; Bifulco M J Biol Chem; 1995 Jun; 270(25):15237-41. PubMed ID: 7797508 [TBL] [Abstract][Full Text] [Related]
5. Restored expression of transforming growth factor beta type II receptor in k-ras-transformed thyroid cells, TGF beta-resistant, reverts their malignant phenotype. Coppa A; Mincione G; Lazzereschi D; Ranieri A; Turco A; Lucignano B; Scarpa S; Ragano-Caracciolo M; Colletta G J Cell Physiol; 1997 Aug; 172(2):200-8. PubMed ID: 9258341 [TBL] [Abstract][Full Text] [Related]
6. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553 [TBL] [Abstract][Full Text] [Related]
7. High glucose induced endothelial cell growth inhibition is associated with an increase in TGFbeta1 secretion and inhibition of Ras prenylation via suppression of the mevalonate pathway. Mather A; Chen XM; McGinn S; Field MJ; Sumual S; Mangiafico S; Zhang Y; Kelly DJ; Pollock CA Int J Biochem Cell Biol; 2009 Mar; 41(3):561-9. PubMed ID: 18692592 [TBL] [Abstract][Full Text] [Related]
8. Farnesylation of p21 Ras proteins in Xenopus oocytes. Zhao J; Kung HF; Manne V Cell Mol Biol Res; 1994; 40(4):313-21. PubMed ID: 7866432 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396 [TBL] [Abstract][Full Text] [Related]
10. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. James G; Goldstein JL; Brown MS Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4454-8. PubMed ID: 8633088 [TBL] [Abstract][Full Text] [Related]
11. Regulation of geranylgeranyl pyrophosphate synthase in the proliferation of rat FRTL-5 cells: involvement of both cAMP-PKA and PI3-AKT pathways. Fuse M; Tanaka T; Shibata T; Yoshida T; Noguchi Y; Misawa N; Yasuda T; Saito Y; Kohn LD; Tatsuno I Biochem Biophys Res Commun; 2004 Mar; 315(4):1147-53. PubMed ID: 14985133 [TBL] [Abstract][Full Text] [Related]
12. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Sun J; Qian Y; Hamilton AD; Sebti SM Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745 [TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Kohl NE; Mosser SD; deSolms SJ; Giuliani EA; Pompliano DL; Graham SL; Smith RL; Scolnick EM; Oliff A; Gibbs JB Science; 1993 Jun; 260(5116):1934-7. PubMed ID: 8316833 [TBL] [Abstract][Full Text] [Related]
14. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells. Gbelcová H; Rimpelová S; Knejzlík Z; Šáchová J; Kolář M; Strnad H; Repiská V; D'Acunto WC; Ruml T; Vítek L Lipids Health Dis; 2017 Dec; 16(1):250. PubMed ID: 29262834 [TBL] [Abstract][Full Text] [Related]
15. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. Cox AD; Garcia AM; Westwick JK; Kowalczyk JJ; Lewis MD; Brenner DA; Der CJ J Biol Chem; 1994 Jul; 269(30):19203-6. PubMed ID: 8034681 [TBL] [Abstract][Full Text] [Related]
16. Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition. Arany PR; Rane SG; Roberts AB Oncogene; 2008 Apr; 27(17):2507-12. PubMed ID: 17952112 [TBL] [Abstract][Full Text] [Related]
17. Effects of the farnesyltransferase inhibitor UCF-1C/manumycin on growth and p21-ras post-translational processing in NIH3T3 cells. Servais P; Gulbis B; Fokan D; Galand P Int J Cancer; 1998 May; 76(4):601-8. PubMed ID: 9590140 [TBL] [Abstract][Full Text] [Related]
18. Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. Ura H; Obara T; Shudo R; Itoh A; Tanno S; Fujii T; Nishino N; Kohgo Y Mol Carcinog; 1998 Feb; 21(2):93-9. PubMed ID: 9496909 [TBL] [Abstract][Full Text] [Related]
19. Geranylgeranyl as well as farnesyl moiety is transferred to Ras p21 overproduced in adrenocortical cells transformed by c-Ha-rasEJ oncogene. Osman H; Mazet JL; Maume G; Maume BF Biochem Biophys Res Commun; 1997 Feb; 231(3):789-92. PubMed ID: 9070894 [TBL] [Abstract][Full Text] [Related]
20. Different analogues of farnesyl pyrophosphate inhibit squalene synthase and protein:farnesyltransferase to different extents. Cohen LH; Valentijn AR; Roodenburg L; Van Leeuwen RE; Huisman RH; Lutz RJ; Van der Marel GA; Van Boom JH Biochem Pharmacol; 1995 Mar; 49(6):839-45. PubMed ID: 7702642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]